News & Events
Bringing a new class of therapeutics to people worldwide
Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA-Based Lead Candidate CDR132L in Heart Failure Patients Post-Myocardial Infarction
Hanover, Germany, July 20, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient in their multicenter Phase 2 trial assessing efficacy and safety of CDR132L in 280 patients with reduced left ventricular ejection fraction after myocardial infarction (HF-REVERT).
Cardior Appoints Dr. Russell Greig as Independent Chairman of the Board
Cardior Appoints Cardiac Disease and RNA Drug Development Experts to its Scientific Advisory Board Supporting Pipeline Expansion in Both Large and Orphan Cardiac Indications
Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease
Hanover, Germany, August 25, 2021 – Cardior Pharmaceuticals GmbH announced today the closing of a €64 million ($76 million) Series B financing round.
Cardior Appoints Dr. Rahul Agrawal as Chief Medical Officer
Hanover, Germany, July 01, 2021 – Cardior Pharmaceuticals GmbH today announced the appointment of Rahul Agrawal, MD, as Chief Medical Officer.
Cardior Pharmaceuticals: Pioneering Study Confirms Pivotal Role of Antisense microRNA Approach in the Treatment of Pathologic Hypertrophy of the Heart
Hanover, Germany, June 24, 2021 – Cardior Pharmaceuticals GmbH announced today that a pioneering study published in the Journal of the American College of Cardiology confirms the pivotal role of its antisense microRNA approach in the treatment of pathologic hypertrophy of the heart.
Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior’s First-in-Class Heart Failure Program
Hanover, Germany, March 29, 2021 – Cardior Pharmaceuticals GmbH announced today that a recent peer-reviewed study confirms the therapeutic mode of action of its lead program CDR132L.
Cardior Pharmaceuticals Announces Positive Phase Ib Results of its Lead Compound CDR132L in Heart Failure
Hanover, Germany, November 12, 2020 – Cardior Pharmaceuticals GmbH announced today positive results of a Phase Ib study with its lead compound CDR132L.
Cardior Pharmaceuticals ́ Lead Compound Demonstrates Improvement of Heart Function in Chronic Heart Failure Mode
Hanover, Germany, October 22, 2020 – Cardior Pharmaceuticals GmbH today announced a publication in the European Heart Journal (doi:10.1093/eurheartj/ehaa791) demonstrating that repeated treatment with its lead compound CDR132L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.
Cardior Pharmaceuticals Demonstrates Reversal of Cardiac Hypertrophy by H19 Gene Therapy
Hanover, Germany, July 13, 2020 – Cardior Pharmaceuticals GmbH today announced the results of extensive in vitro and in vivo studies demonstrating the therapeutic potential of H19 gene therapy to combat cardiac hypertrophy and heart failure.
Cardior’s pioneering miRNA approach in heart failure endorsed by expert opinions in the European Heart Journal
Hanover, Germany, February 9, 2020 – Cardior Pharmaceuticals GmbH announced today that the Phase Ib results as well as preclinical and large-animal data of the Company’s lead compound CDR132L were published alongside with two editorials from independent experts in the European Heart Journal Volume 42, Issue 3, January 14, 2021, an issue focusing on ischemic heart diseases.
Cardior Receives EUR 1.01 Million Grant to Identify Novel Oligonucleotides for th e Treatment of Chronic Heart Failure
Hanover, Germany, December 11, 2018 – Cardior Pharmaceuticals GmbH today announced it has been granted EUR 1.01 million funding for a joint research project with the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH).
Cardior strengthens patent portfolio of miRNAs for the diagnosis and therapy of heart and kidney diseases
Hanover, Germany, November 1, 2018 – Cardior Pharmaceuticals GmbH today announced it has acquired a portfolio of four microRNA (miRNA) patents from Bayerische Patentallianz GmbH (BayPAT).
Cardior Pharmaceuticals raises €15 million and appoints CEO and CSO
Hannover, Germany, May 11, 2017 – Cardior Pharmaceuticals today announced the completion of a €15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol - Myers Squibb (BMS), BioMedPartners (with its new BioMedInvest III Fund) and High - Tech Gründerfonds (HTGF).
You would like to get in touch with us? Meet us at:
Cardior’s CSO Prof. Thomas Thum receives prestigious Paul-Martini-Award for his achievements in developing novel, causative heart failure treatments
Cardior's CSO Prof. Dr. Dr. med. Thomas Thum received the Paul Martini Award for the conception and initial testing of a new form of therapy for cardiac insufficiency - also known as heart failure. The prize is awarded annually by the Paul Martini Foundation, Berlin, for outstanding achievements in clinical therapeutic drug research.
Cardior featured in BioCentury
Cardior is featured in the BioCentury issue of January 4, 2021 with the “Emerging Company Profile”.
Cardior featured in BioWorld
Cardior is featured in the BioWorld issue of January 7, 2019 with the “Newco News”.